India Human Papillomavirus Vaccine Market to be grow by 6.11% through 2030
The increase in awareness about
human papillomavirus vaccines among consumers is expected to drive the India
human papillomavirus vaccine market during the forecast period, 2026-2030
According to the TechSci Research report, “India
Human Papillomavirus Vaccine Market - By Region, Competition, Forecast, and
Opportunities, 2030F”, The India Human Papillomavirus Vaccine Market was valued at
USD 72.11 Million in 2024 and is expected to reach USD 102.10 Million by 2030,
growing with a CAGR of 6.11% in the forecast period.
The India human papillomavirus vaccine market
experienced significant growth in recent years. Multi-valent human
papillomavirus vaccines are formulated to protect against multiple strains of
the virus, unlike the bivalent vaccine which targets only two strains.
Quadrivalent and nonavalent human papillomavirus vaccines are the two
multi-valent options currently available in India, offering broader protection,
including against strains linked to a higher risk of cervical cancer. The
adoption of multi-valent human papillomavirus vaccines in India has been fueled
by various factors such as heightened awareness of cervical cancer risks,
improved healthcare access, and the availability of newer, more effective
vaccines. Their uptake is expected to keep rising, contributing to market
expansion in the coming years. Notable trends include a growing focus on
public-private partnerships, which aim to develop and distribute HPV vaccines
across India. This joint effort is set to promote innovation, lower costs, and
enhance vaccine accessibility throughout the forecast period.
Government bodies, non-governmental organizations, and
healthcare institutions are working to improve HPV vaccine reach in rural
regions with limited infrastructure through initiatives like mobile health
units, educational programs, and subsidized immunization schemes. Despite this
growth, vaccine hesitancy remains a significant barrier, driven by safety,
efficacy, and side effect concerns among certain groups.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on the “India Human Papillomavirus
Vaccine Market”
The India human papillomavirus
vaccine market can be segmented by valence, disease indication,
distribution channel, and region.
Based on distribution
channel, Hospitals and clinics dominated the India Human Papillomavirus (HPV)
vaccine market due to their established role as the primary healthcare access
points for vaccination, diagnosis, and preventive care. These facilities are
trusted by patients and are well-equipped with the necessary infrastructure,
such as trained medical staff and cold chain systems, to safely administer
vaccines. The availability of gynecologists, pediatricians, and general
physicians in hospitals and clinics makes it easier to counsel patients on the
importance of HPV vaccination and address concerns about safety and efficacy,
thereby increasing vaccine uptake. Urban and semi-urban populations often rely
on hospitals and clinics for routine immunization, which has positioned these
settings as the most reliable and accessible venues for HPV vaccination. Many
private hospitals also actively promote HPV vaccination through awareness
programs and consultations, especially for adolescent girls and young women. In
public healthcare settings, clinics are key touchpoints in school-based
vaccination campaigns and government immunization drives. Their presence in
both rural and urban areas supports broader vaccine distribution. These
facilities also provide integrated care, including cervical cancer screening,
which allows for a more comprehensive approach to HPV prevention. Their
credibility, medical expertise, and infrastructure make hospitals and clinics
the dominant channels in India’s HPV vaccine market.
Major companies operating in the
India Human Papillomavirus Market are:
·
Bharat Biotech International Ltd
·
HLL Lifecare Limited
·
Panacea Biotec Limited
·
MSD Pharmaceuticals Private Limited
·
Serum Institute of India
·
GlaxoSmithKline Pharmaceuticals
Ltd.
·
Beijing Health Guard Biotechnology,
Inc.
·
Shanghai Bovax Biotechnology Co.
·
Serum Institute of India Pvt. Ltd.
·
Johnson & Johnson (Janssen
Biotech, Inc.).
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“The India human papillomavirus (HPV) vaccine market was poised for significant growth due to the increasing incidence of cancers
linked to HPV, including vulvar, vaginal, and oropharyngeal cancers. Though
still in its early stages, the market is expected to expand rapidly with the
integration of HPV vaccines into the national immunization program. Growing
awareness about cervical cancer prevention, rising focus on healthier
lifestyles, and increased spending on healthcare are all contributing to the
market’s positive outlook and long-term potential” said Mr. Karan Chechi,
Research Director of TechSci Research, a research-based global management
consulting firm.
"India Human Papillomavirus Vaccine Market By Valence (Bivalent, Quadrivalent, Nonvalent, and Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, and Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, and Others), By Region, Competition, Forecast & Opportunities, 2020-2030F", has
evaluated the future growth potential of the India human papillomavirus
vaccine market and provides statistics & information on market size,
structure, and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in the India human
papillomavirus vaccine market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com